Study of Calcitonin Treatment to Improve SPECT-CT Scan Accuracy for Detecting Parathyroid Adenoma in Primary Hyperparathyroidism

What this Trial Is About

This research focuses on patients diagnosed with primary hyperparathyroidism who have had a SPECT-CT scan that did not clearly locate the parathyroid adenoma within the past year. The study aims to find out if lowering calcium levels with calcitonin before repeating the scan can improve the ability of SPECT-CT to detect the parathyroid adenoma. This is a phase 4 interventional trial sponsored by Joseph Sferra. Participants will receive calcitonin injections at a dose of 200 IU twice daily for two days, followed by a single dose on the day of the second SPECT-CT imaging. This treatment is intended to lower calcium levels prior to the scan. All subjects will be in this treatment group, and the study focuses on evaluating the sensitivity of the SPECT-CT after calcitonin pre-treatment. During the study, participants will undergo a second SPECT-CT scan to assess changes in imaging sensitivity. Researchers will monitor the success of the imaging and surgical outcomes over six months following surgery. The primary outcome is the sensitivity of the SPECT-CT one year after treatment, with secondary outcomes including surgical approach and success rate. Participants will be followed for safety and treatment results throughout the study period ending in 2026.

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity